Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

NORDIC HEALTH INNOVATIONS ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   24.4% 25.7% 13.5% 13.6% 10.4% 7.5% 20.6% 20.4%   Credit score (0-100)   4 3 16 15 23 31 5 5   Credit rating   B B BB BB BB BB B B   Credit limit (kDKK)   -0.0 -0.0 -0.0 -0.0 0.0 0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -28.7 -158 757 2,852 5,256 4,645 0.0 0.0   EBITDA   -28.7 -602 47.2 449 573 796 0.0 0.0   EBIT   -97.3 -738 -113 333 524 796 0.0 0.0   Pre-tax profit (PTP)   -135.5 -811.0 -244.6 229.7 500.6 770.0 0.0 0.0   Net earnings   -135.5 -811.0 -244.6 229.7 712.4 599.4 0.0 0.0   Pre-tax profit without non-rec. items   -135 -811 -245 230 501 770 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   -616 -1,427 -1,672 -1,442 -730 -131 -181 -181   Interest-bearing liabilities   0.0 0.0 0.0 0.0 3,808 3,377 181 181   Balance sheet total (assets)   236 767 1,111 1,551 3,079 3,282 0.0 0.0   Net Debt   -12.6 -331 -726 -1,362 2,361 500 181 181     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -28.7 -158 757 2,852 5,256 4,645 0.0 0.0   Gross profit growth   64.0% -450.1% 0.0% 276.5% 84.3% -11.6% -100.0% 0.0%   Employees   0 1 0 2 4 4 0 0   Employee growth %   0.0% 0.0% -100.0% 0.0% 100.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   236 767 1,111 1,551 3,079 3,282 0 0   Balance sheet change%   -27.6% 225.6% 44.8% 39.7% 98.4% 6.6% -100.0% 0.0%   Added value   -28.7 -601.7 47.2 448.8 640.4 796.5 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -24 20 -320 -232 -97 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -2.0 -3.0 -4.0 1.0 2.0 3.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   338.6% 466.6% -14.9% 11.7% 10.0% 17.1% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -11.6% -48.3% -4.5% 11.5% 15.4% 22.1% 0.0% 0.0%   ROI %   -12.1% -49.6% -5.1% 15.4% 17.9% 22.2% 0.0% 0.0%   ROE %   -48.3% -161.8% -26.1% 17.3% 30.8% 18.8% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   -72.3% -65.0% -60.1% -48.2% -19.2% -3.8% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   44.0% 55.0% -1,536.5% -303.5% 412.1% 62.8% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% -521.7% -2,586.7% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 1.2% 0.7% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   1.7 10.9 1.8 1.6 1.8 2.5 0.0 0.0   Current Ratio   1.7 10.9 1.8 1.6 1.8 2.5 0.0 0.0   Cash and cash equivalent   12.6 330.7 725.6 1,362.3 1,447.3 2,876.9 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   27.1 389.8 423.5 558.6 1,340.1 1,960.7 -90.3 -90.3   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 -602 0 224 160 199 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 -602 0 224 143 199 0 0   EBIT / employee   0 -738 0 166 131 199 0 0   Net earnings / employee   0 -811 0 115 178 150 0 0